Table of Contents: 1 Report Prologue 2 Market Introduction 2.1 Scope of Study 2.2 Research Objective 2.3 Assumptions & Limitations 2.3.1 Assumptions 2.3.2 Limitations 3 Research Methodology 3.1 Primary Research Methodology 3.2 Secondary Research Methodology 3.3 Market Share Analysis 3.4 Trade Analysis 3.5 Market Pricing Approach 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD) 4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth 4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease 4.3 Restraints 4.3.1 Weak Product Pipeline of First Drugs for Autism 4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options 4.4 Opportunities 4.4.1 Rising Investments by Venture Non-Pharmacology Activities 4.5 Mega Trends 4.6 Macroeconomic Indicators 5 Market Factor Analysis 5.1 Porter’s Five Forces Model 5.1.1 Bargaining Power of Suppliers 5.1.2 Bargaining Power of Buyers 5.1.3 Threat of New Entrants 5.1.4 Threat of Substitutes 5.1.5 Intensity of Rivalry 5.2 Value Chain Analysis 5.2.1 R&D 5.2.2 Manufacturing 5.2.3 Distribution & Sales 5.2.4 Post-Sales Monitoring 5.3 Pricing Analysis 5.4 Investment Opportunity Analysis 5.5 Demand & Supply: Gap Analysis 6 Global Autism Disorder & Treatment Market, By Type 6.1 Introduction 6.2 Asperger Syndrome 6.3 Pervasive Developmental Disorders (PDD) 7 Global Autism Disorder & Treatment Market, By Treatment Type 7.1 Introduction 7.2 Expert Opinion: Oxytocin 7.3 ABA (applied behavioral analysis) 7.4 Hyperbaric oxygen therapy 7.5 Chelation therapy 7.6 Oxytocin therapy 8 Global Autism Disorder & Treatment Market, By Drugs 8.1 Introduction 8.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 8.3 Anti-convulsants 8.4 Stimulants 8.5 Anti-psychotic 9 Global Autism Disorder & Treatment Market, By Region 9.1 Introduction 9.2 Americas 9.3 North America 9.3.1 U.S. 9.4 Canada 9.4.1 South America 9.5 Europe 9.5.1 Germany 9.5.2 France 9.5.3 U.K. 9.5.4 Italy 9.5.5 Spain 9.5.6 Rest of Western Europe 9.5.7 Eastern Europe 9.6 Asia Pacific 9.6.1 Japan 9.6.2 China 9.6.3 India 9.6.4 Australia 9.6.5 Republic of Korea 9.6.6 Rest of Asia Pacific 9.7 Middle East & Africa 9.7.1 U.A.E. 9.7.2 Saudi Arabia 9.7.3 Oman 9.7.4 Kuwait 9.7.5 Qatar 9.7.6 Rest of the Middle East & Africa 10 Competitive Landscape 10.1 Company Market Share Analysis 10.1.1 Introduction 10.2 Competitive Landscape 10.2.1 Introduction 10.3 Recent Developments, 2013–2018 11 Company Profiles 11.1 Pfizer Inc. 11.1.1 Company Overview 11.1.2 Financials 11.1.3 Products 11.1.4 Strategy 11.1.5 Key Developments 11.2 Allergan, Plc 11.2.1 Company Overview 11.2.2 Financials 11.2.3 Products 11.2.4 Strategy 11.2.5 Key Developments 11.3 Eli Lilly and Company 11.3.1 Company Overview 11.3.2 Financials 11.3.3 Products 11.3.4 Strategy 11.3.5 Key Developments 11.4 Bristol-Myers Squibb Company 11.4.1 Company Overview 11.4.2 Financials 11.4.3 Products 11.4.4 Strategy 11.4.5 Key Developments 11.5 Sun Pharmaceutical Industries Ltd. 11.5.1 Company Overview 11.5.2 Financials 11.5.3 Products 11.5.4 Strategy 11.5.5 Key Developments 11.6 Johnson & Johnson Services, Inc. 11.6.1 Company Overview 11.6.2 Financials 11.6.3 Products 11.6.4 Strategy 11.6.5 Key Developments 11.7 Teva Pharmaceutical Industries Ltd. 11.7.1 Company Overview 11.7.2 Financials 11.7.3 Products 11.7.4 Strategy 11.7.5 Key Developments 11.8 Merck & Co. Inc 11.8.1 Company Overview 11.8.2 Financials 11.8.3 Products 11.8.4 Strategy 11.8.5 Key Developments 11.9 Novartis AG 11.9.1 Company Overview 11.9.2 Financials 11.9.3 Products 11.9.4 Strategy 11.9.5 Key Developments 11.1 Otsuka Holdings Co. Ltd 11.10.1 Company Overview 11.10.2 Financials 11.10.3 Products 11.10.4 Strategy 11.10.5 Key Developments 11.11 Consern Pharma Private Limited 12 Conclusion 12.1 Key Findings 12.1.1 CEO’s Viewpoint 12.1.2 Key Companies to Watch 12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry 13 Appendix 13.1 Discussion Blue Print 13.2 Expert Opinion: Oxytocin 13.3 References

List of Tables: TABLE 1 MARKET SYNOPSIS TABLE 2 PRIMARY INTERVIEWS TABLE 3 GLOBAL AUTISM DISORDER & TREATMENT, BY TYPE, 2014–2023, (USD MILLION) TABLE 4 GLOBAL AUTISM DISORDER & TREATMENT FOR ASPERGER SYNDROME , BY REGION, 2014–2023, (USD MILLION) TABLE 5 GLOBAL AUTISM DISORDER & TREATMENT FOR PERVASIVE DEVELOPMENTAL DISORDER, BY REGION, 2014–2023 (USD MILLION) TABLE 6 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 7 GLOBAL AUTISM DISORDER & TREATMENT FOR ABA (APPLIED BEHAVIORAL ANALYSIS), BY REGION, 2014–2023, (USD MILLION) TABLE 8 GLOBAL AUTISM DISORDER & TREATMENT FOR HYPERBARIC OXYGEN THERAPY, BY REGION, 2014–2023, (USD MILLION) TABLE 9 GLOBAL AUTISM DISORDER & TREATMENT FOR CHELATION THERAPY, BY REGION, 2014–2023, (USD MILLION) TABLE 10 GLOBAL AUTISM DISORDER & TREATMENT FOR OXYTOCIN THERAPY, BY REGION, 2014–2023, (USD MILLION) TABLE 11 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 12 GLOBAL AUTISM DISORDER & TREATMENT FOR SSRIS, BY REGION, 2014–2023, (USD MILLION) TABLE 13 GLOBAL AUTISM DISORDER & TREATMENT FOR ANTI-CONVULSANTS, BY REGION, 2014–2023, (USD MILLION) TABLE 14 GLOBAL AUTISM DISORDER & TREATMENT FOR STIMULANTS, BY REGION, 2014–2023, (USD MILLION) TABLE 15 GLOBAL AUTISM DISORDER & TREATMENT FOR ANTI-PSYCHOTIC, BY REGION, 2014–2023, (USD MILLION) TABLE 16 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2014–2023, (USD MILLION) TABLE 17 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014–2023, (USD MILLION) TABLE 18 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 19 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 20 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 21 U.S. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 22 U.S. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 23 U.S. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 24 CANADA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 25 CANADA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 26 CANADA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 27 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 28 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 29 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 30 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014–2023, (USD MILLION) TABLE 31 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 32 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 33 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 34 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 35 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 36 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 37 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 38 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 39 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 40 U.K. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 41 U.K. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 42 U.K. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 43 ITALY AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 44 ITALY AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 45 ITALY AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 46 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 47 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 48 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 49 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 50 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 51 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 52 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 53 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 54 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 55 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014–2023, (USD MILLION) TABLE 56 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 57 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 58 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 59 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 60 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 61 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 62 CHINA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 63 CHINA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 64 CHINA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 65 INDIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 66 INDIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 67 INDIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 68 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 69 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 70 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 71 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 72 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 73 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 74 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 75 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 76 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 77 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014–2023, (USD MILLION) TABLE 78 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 79 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 80 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 81 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 82 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 83 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 84 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 85 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 86 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 87 OMAN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 88 OMAN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 89 OMAN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 90 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 91 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 92 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 93 QATAR AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 94 QATAR AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 95 QATAR AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) TABLE 96 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014–2023, (USD MILLION) TABLE 97 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014–2023, (USD MILLION) TABLE 98 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014–2023, (USD MILLION) List of Figures: FIGURE 1 GLOBAL AUTISM DISORDER & TREATMENT MARKET: MARKET STRUCTURE FIGURE 2 RESEARCH METHODOLOGY FIGURE 3 PORTERS FIVE FORCES MODEL FIGURE 4 VALUE CHAIN: GLOBAL AUTISM DISORDER & TREATMENT MARKET FIGURE 5 GLOBAL AUTISM DISORDER & TREATMENT, BY TYPE, 2016 & 2023 (USD MILLION) FIGURE 6 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2016 & 2023 (USD MILLION) FIGURE 7 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2016 & 2023 (USD MILLION) FIGURE 8 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2016 & 2023 (USD MILLION) FIGURE 9 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2017 (%) FIGURE 10 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2017 (%) FIGURE 11 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2017 (%) FIGURE 12 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2017 (%) FIGURE 13 GLOBAL AUTISM DISORDER & TREATMENT MARKET, COMPANY SHARE ANALYSIS 2016 (%) FIGURE 14 GLOBAL AUTISM DISORDER & TREATMENT MARKET COMPETITIVE LANDSCAPE 2016 (%)

Pfizer Inc., Allergan, Eli Lilly and Company, Saniona AB, Merck & CO Inc., Consern Pharma Private Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Johnson & Johnson Services, Inc., Coronis Partners Ltd., Heptares Therapeutics Limited, Curemark LLC, Intra-Cellular Therapies Inc., among others